top of page

Understanding the China Appeal and Our Growing Clinical Trial Deficit

Oct 26
3 min read

By Penn Quarter Partners


At a major health care innovation conference hosted by Mass General Brigham, the medical director for one of the largest pharmaceutical companies explained to the audience why his firm is conducting more of its clinical trials in China.


In China, he explained, there is faster patient enrollment in clinical studies and more rapid trial execution. Clinical study teams gain operational expertise more quickly, and critical lessons — in areas such as optimal dosing — emerge expeditiously. In the United States, he said, there is not the same level of learning at individual trial sites.


As competition for global leadership in biopharmaceutical development has intensified in recent years, potentially threatening the pole position held by the U.S. for decades, much of the focus has rightly been on the adverse impacts of U.S. policymaking aimed at controlling prescription drug prices.


This remains a significant concern, but there also is increasing awareness of the factors leading to an American clinical trial deficit, exemplified by more U.S.-based companies testing their new innovations in other countries, particularly China. 


A recent guest essay in the New York Times described how the federal regulatory infrastructure governing how clinical trials are conducted in the United States is leading to slower and costlier trials. The essayist pointed out that the number of new drugs approved for the marketplace per billion dollars of research and development spending has been cut in half every nine years since the 1950s, also noting that the conventional clinical study approach involving large numbers of patients is not well suited for a new generation of precision medicines and treatments custom-designed for individuals.


There are serious ramifications to more clinical testing leaving the United States and moving overseas. American patients are losing opportunities to be part of trials for novel therapies that can address their unmet health needs. Clinical trials generate significant economic activity that cannot be replaced if those studies are shifted to China or other countries. And, most importantly, clinical testing overseas increases the likelihood that people in the U.S. won’t be the first to have access to new breakthrough treatments.


Encouragingly, the issue is gaining attention within regulatory and policy circles. In June, the Department of Health and Human Services announced the creation of Operation TrialBlazer, a multi-faceted initiative that involves actions such as FDA reforms aimed at reducing early trial timelines by six months to a year and the Advanced Research Projects Agency for Health (ARPA-H) examining ways to use AI to improve trial efficiencies before patients are even enrolled.


In addition, the commitment letter recently negotiated by FDA and industry representatives to reauthorize the Prescription Drug User Fee Act (PDUFA VIII) includes provisions related to clinical trials. As summarized by PhRMA, program improvements will enhance the “consistency, quality, and timeliness of FDA-sponsor interactions on pivotal clinical trial protocols, labeling and manufacturing that can affect review timelines.”


Such enhancements will be considered by Congress next year as PDUFA moves through the legislative process.


The medical director suggested, as well, that academic health centers in the U.S. should undergo their own self-examination and engagement in strategic partnerships to increase their clinical study efficacy. This makes good sense, as all collaborators in our dynamic ecosystem must continually evolve to drive science forward.


This is a sphere in which reasserting U.S. leadership matters greatly.  As a firm that works with companies through every step of the product lifecycle from invention and development to commercialization, Penn Quarter Partners is closely monitoring and supporting efforts to strengthen our nation’s clinical study infrastructure. 

 
 
bottom of page